This transgene results from the coinjection of two constructs derived from CD4+ T cell clones that react with the Kd54-68/I-Ab epitope. The Tcra construct uses V alpha 11.2 and J alpha 25. The Tcrb construct uses V beta 13 and J beta 1.6. Both constructs are under the control of the human CD2 promoter. (J:155849)